In the first half of 2025, NeuroBlu has transformed into the industry's most comprehensive real-world evidence (RWE) platform for psychiatric and neurological research. With seven major releases, we’ve expanded our reach across therapeutic areas and pharma departments delivering on our mission to support data-driven innovation in mental health and neurodegenerative disease drug development.

NeuroBlu now empowers stakeholders across the pharma value chain to explore, analyze, and act on high-quality real-world data with confidence and speed.

The Transformation in Numbers

• 36M+ patients with behavioral and neurological conditions
• 2M+ new patients added in H1 2025
• 16+ new features added across analytics and data capabilities
• 5 pharma departments supported with tailored tools
• <1 Minute performance for complex queries

Key Platform Enhancements

Data Expansion

NeuroBlu’s dataset has grown significantly—both in scale and clinical depth.

• 1.9M+ new patients added via major dataset refreshes (Feb & May)
• 4 new cognitive assessments: MoCA, MMSE, MiniCog, ESS
• Expanded psychiatric scales: PC-PTSD-5, PCL-5, and PSS-3
• First platform with integrated psychotherapy + EEG procedure analysis

Expanded Support for Dementia and Cognitive Disorders

NeuroBlu now offers unprecedented cognitive assessment coverage for dementia, movement disorders, and related conditions. With 1.8M+ dementia patients and complete cognitive batteries available, the platform enables precise research into disease progression, comorbidities, and real-world treatment pathways.

Unique Differentiators:

• 1.8M+ dementia patients with linked cognitive assessments
• Comprehensive battery: MoCA (13K+), MMSE (37K+), MiniCog (430K+)
• Track progression from mild cognitive impairment (MCI) to severe dementia
• Sleep data integration with ESS (116K+ patients) for related symptom tracking

Analytics Innovation

We’ve introduced tools that make real-world evidence generation faster, more flexible, and easier to scale.

• Seamless workflows: Navigate directly from Cohort Explorer to SQL Studio
• Department-specific SQL templates: Pre-built queries tailored to HEOR, Clinical Development, Epidemiology, and more
• 26 new packages (17 R, 9 Python) for causal inference, survival analysis, and machine learning
• Density Timeline: Visualize clinical events across the patient journey
• Resources Hub: Centralized documentation and training materials now easily accessible to all users

Built for Pharma Expanding Capabilities Across the Value Chain

NeuroBlu has evolved to serve every department across the pharma value chain with tailored capabilities, accelerating evidence generation and decision-making.

Real-World Data (RWD)

From question to insight in hours, not months

Unified access to standardized data across behavioral and neurological conditions, fast cohort building, direct querying, and no-code exploration—all with significant time and cost savings.

Clinical Development

Design trials that succeed using real-world intelligence

Optimize inclusion/exclusion criteria, select ideal sites, and model external control arms with regulatory-grade support—boosting trial design precision and success rates.

Epidemiology

Understand true disease burden and natural history

Leverage population-level trends, disease progression data, and phenotype insights to inform publications, pipelines, and global burden assessments.

Health Economics & Outcomes Research (HEOR)

Prove value with clinical and economic evidence

Conduct outcomes analysis using validated scales, model cost-effectiveness, and deliver compelling comparative effectiveness studies for payers and policy.

Medical Affairs

Generate and share real-world insights that matter

Support scientific exchange with fast, publication-ready analyses and KOL-aligned data—powered by the Resources hub for collaborative research.

Enterprise Capabilities

As adoption scales across large organizations, NeuroBlu now meets the needs of global pharma teams with:

• Flexible authentication: Support for multiple SSO/SAML integrations
• Universal platform search: Sub-second access to datasets, queries, and documentation
• Offline-ready documentation: Download key guides and specifications for secure, collaborative workflows
• Improved analysis visibility: 10x boost in performance monitoring and console clarity for complex analytics

NeuroBlu’s rapid evolution in H1 2025 reflects our deep commitment to powering the next generation of real-world research in psychiatry and neurology. With richer data, smarter tools, and enterprise-grade performance, we’re proud to be the RWE platform of choice for modern drug development.

Interested in seeing NeuroBlu Analytics for yourself? Contact us to schedule a demo.

Already a customer? Log in here.

‍